These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 22174609)

  • 81. Disturbance of circadian gene expression in breast cancer.
    Kuo SJ; Chen ST; Yeh KT; Hou MF; Chang YS; Hsu NC; Chang JG
    Virchows Arch; 2009 Apr; 454(4):467-74. PubMed ID: 19296127
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Role of Melatonin in Breast Carcinoma: Correlation of Expression Patterns of Melatonin-1 Receptor With Estrogen, Progesterone, and HER2 Receptors.
    Goyal R; Gupta T; Bal A; Sahni D; Singh G
    Appl Immunohistochem Mol Morphol; 2020 Aug; 28(7):518-523. PubMed ID: 31290783
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Expression of LRP and MDR1 in locally advanced breast cancer predicts axillary node invasion at the time of rescue mastectomy after induction chemotherapy.
    Schneider J; Gonzalez-Roces S; Pollán M; Lucas R; Tejerina A; Martin M; Alba A
    Breast Cancer Res; 2001; 3(3):183-91. PubMed ID: 11305953
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Evaluation of changes of biologic markers ER, PR, HER 2 and Ki-67 in breast cancer with administration of neoadjuvant dose-dense doxorubicin, cyclophosphamide followed by paclitaxel.
    Dede DS; Gumuskaya B; Guler G; Onat D; Altundag K; Ozisik Y
    J BUON; 2013; 18(1):57-63. PubMed ID: 23613389
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Definition of p53 overexpression and its association with the clinicopathological features in luminal/HER2-negative breast cancer.
    Kikuchi S; Nishimura R; Osako T; Okumura Y; Nishiyama Y; Toyozumi Y; Arima N
    Anticancer Res; 2013 Sep; 33(9):3891-7. PubMed ID: 24023325
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Neoadjuvant chemotherapy reduces the expression rates of ER, PR, HER2, Ki67, and P53 of invasive ductal carcinoma.
    Peng JH; Zhang X; Song JL; Ran L; Luo R; Li HY; Wang YH
    Medicine (Baltimore); 2019 Jan; 98(2):e13554. PubMed ID: 30633152
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Levels of hypoxia-inducible factor-1 alpha during breast carcinogenesis.
    Bos R; Zhong H; Hanrahan CF; Mommers EC; Semenza GL; Pinedo HM; Abeloff MD; Simons JW; van Diest PJ; van der Wall E
    J Natl Cancer Inst; 2001 Feb; 93(4):309-14. PubMed ID: 11181778
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Correlation between genetic and biological aspects in primary non-metastatic breast cancers and corresponding synchronous axillary lymph node metastasis.
    D'Andrea MR; Limiti MR; Bari M; Zambenedetti P; Montagutti A; Ricci F; Pappagallo GL; Sartori D; Vinante O; Mingazzini PL
    Breast Cancer Res Treat; 2007 Mar; 101(3):279-84. PubMed ID: 16835704
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Progesterone receptor loss correlates with human epidermal growth factor receptor 2 overexpression in estrogen receptor-positive breast cancer.
    Kim HJ; Cui X; Hilsenbeck SG; Lee AV
    Clin Cancer Res; 2006 Feb; 12(3 Pt 2):1013s-1018s. PubMed ID: 16467118
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Tumour biomarker expression relative to age and molecular subtypes of invasive breast cancer.
    Morrison DH; Rahardja D; King E; Peng Y; Sarode VR
    Br J Cancer; 2012 Jul; 107(2):382-7. PubMed ID: 22713661
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Tumor size and proliferative marker geminin rather than Ki67 expression levels significantly associated with maximum uptake of 18F-deoxyglucose levels on positron emission tomography for breast cancers.
    Nishimukai A; Inoue N; Kira A; Takeda M; Morimoto K; Araki K; Kitajima K; Watanabe T; Hirota S; Katagiri T; Nakamori S; Akazawa K; Miyoshi Y
    PLoS One; 2017; 12(9):e0184508. PubMed ID: 28886153
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Targeting DNA replication before it starts: Cdc7 as a therapeutic target in p53-mutant breast cancers.
    Rodriguez-Acebes S; Proctor I; Loddo M; Wollenschlaeger A; Rashid M; Falzon M; Prevost AT; Sainsbury R; Stoeber K; Williams GH
    Am J Pathol; 2010 Oct; 177(4):2034-45. PubMed ID: 20724597
    [TBL] [Abstract][Full Text] [Related]  

  • 93. The Relationship of GATA3 and Ki-67 With Histopathological Prognostic Parameters, Locoregional Recurrence and Disease-free Survival in Invasive Ductal Carcinoma of the Breast.
    Yildirim E; Bektas S; Gundogar O; Findik D; Alcicek S; Erdogan KO; Yildiz M
    Anticancer Res; 2020 Oct; 40(10):5649-5657. PubMed ID: 32988889
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Prognostic factors in Hungarian breast cancer patients.
    Nádasi E; Anga B; Sándor J; Megyesi J; Kelemen D; Mottolese M; Natali PG; Hegedus G; Arany I; Ember I
    Anticancer Res; 2007; 27(1A):279-82. PubMed ID: 17352244
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Clinicopathological significance of ATM-Chk2 expression in sporadic breast cancers: a comprehensive analysis in large cohorts.
    Abdel-Fatah TM; Arora A; Alsubhi N; Agarwal D; Moseley PM; Perry C; Doherty R; Chan SY; Green AR; Rakha E; Ball G; Ellis IO; Madhusudan S
    Neoplasia; 2014 Nov; 16(11):982-91. PubMed ID: 25425972
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Prediction of nodal metastasis and prognosis of breast cancer by ANN-based assessment of tumour size and p53, Ki-67 and steroid receptor expression.
    Mojarad S; Venturini B; Fulgenzi P; Papaleo R; Brisigotti M; Monti F; Canuti D; Ravaioli A; Woo L; Dlay S; Sherbet GV
    Anticancer Res; 2013 Sep; 33(9):3925-33. PubMed ID: 24023330
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Correlation of B-cell lymphoma 2 immunoexpression in invasive carcinoma of breast, no special type with hormone receptor status, proliferation index, and molecular subtypes.
    Azmat H; Faridi J; Habib HM; Bugti UJ; Sheikh AK; Riaz SK
    J Cancer Res Ther; 2022 Dec; 18(Supplement):S313-S319. PubMed ID: 36510982
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Transcriptional profiling reveals a subset of human breast tumors that retain wt TP53 but display mutant p53-associated features.
    Benor G; Fuks G; Chin SF; Rueda OM; Mukherjee S; Arandkar S; Aylon Y; Caldas C; Domany E; Oren M
    Mol Oncol; 2020 Aug; 14(8):1640-1652. PubMed ID: 32484602
    [TBL] [Abstract][Full Text] [Related]  

  • 99. LdrB Toxin with In Vitro and In Vivo Antitumor Activity as a Potential Tool for Cancer Gene Therapy.
    Jiménez-Martínez Y; Griñán-Lisón C; Khaldy H; Martín A; Cambrils A; Ibáñez Grau A; Jiménez G; Marchal JA; Boulaiz H
    Cancers (Basel); 2019 Jul; 11(7):. PubMed ID: 31330822
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Deciphering the Mechanism of Action Involved in Enhanced Suicide Gene Colon Cancer Cell Killer Effect Mediated by Gef and Apoptin.
    Cáceres B; Ramirez A; Carrillo E; Jimenez G; Griñán-Lisón C; López-Ruiz E; Jiménez-Martínez Y; Marchal JA; Boulaiz H
    Cancers (Basel); 2019 Feb; 11(2):. PubMed ID: 30813432
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.